Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for moderately to severely active ulcerative colitis
NL-OMON54924Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in autoimmune colitis (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical response at Week I-12 and Clinical remission at Week M-44. Planned start Sep 2019; status: withdrawn.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54924.